These mechanisms occur within hours after GCs administration and may lead to hyperglycemia, even in individuals without a prior history of glucose abnormalities ( Figure 1 The clinical impact of hyperglycemia during GCs therapy has been well established, with multiple studies reporting increased morbidity and mortality, including higher rates of infection, cardiovascular events and prolonged hospitalisations ( Although glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are not currently recommended in SID by major guidelines, their mechanism of action makes them promising candidates to counteract the metabolic impacts of steroids
They were soon authorized as weight-loss methods for non-diabetic individuals
Also, it is associated with it is a phenomenon of resistance to conventional treatment
Yes, GLP-1 medications work best when combined with healthy lifestyle changes
Debate over GLP-1s Will Intensify in 2025 As 2025 quickly approaches, GLP-1s are at the center of cost containment efforts
Both problems are fixable